4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

974.29p
   
  • Change Today:
    -10.71p
  • 52 Week High: 1,600.00p
  • 52 Week Low: 974.29p
  • Currency: UK Pounds
  • Shares Issued: 15.50m
  • Volume: 0
  • Market Cap: £150.98m

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth
87.39% above the market average87.39% above the market average87.39% above the market average87.39% above the market average87.39% above the market average
53.33% above the sector average53.33% above the sector average53.33% above the sector average53.33% above the sector average53.33% above the sector average

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
94.01% above the market average94.01% above the market average94.01% above the market average94.01% above the market average94.01% above the market average
84.62% above the sector average84.62% above the sector average84.62% above the sector average84.62% above the sector average84.62% above the sector average
Price Book Ratio
83.94% below the market average83.94% below the market average83.94% below the market average83.94% below the market average83.94% below the market average
53.85% below the sector average53.85% below the sector average53.85% below the sector average53.85% below the sector average53.85% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
84.89% below the market average84.89% below the market average84.89% below the market average84.89% below the market average84.89% below the market average
73.91% below the sector average73.91% below the sector average73.91% below the sector average73.91% below the sector average73.91% below the sector average
Price Chg 3m
69.78% below the market average69.78% below the market average69.78% below the market average69.78% below the market average69.78% below the market average
52.17% below the sector average52.17% below the sector average52.17% below the sector average52.17% below the sector average52.17% below the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
82.64% below the market average82.64% below the market average82.64% below the market average82.64% below the market average82.64% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Momentum 20
96.35% below the market average96.35% below the market average96.35% below the market average96.35% below the market average96.35% below the market average
95.24% below the sector average95.24% below the sector average95.24% below the sector average95.24% below the sector average95.24% below the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
94.28% below the market average94.28% below the market average94.28% below the market average94.28% below the market average94.28% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
54.66% below the market average54.66% below the market average54.66% below the market average54.66% below the market average54.66% below the market average
4.35% below the sector average4.35% below the sector average4.35% below the sector average4.35% below the sector average4.35% below the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
82.02% below the market average82.02% below the market average82.02% below the market average82.02% below the market average82.02% below the market average
56.25% below the sector average56.25% below the sector average56.25% below the sector average56.25% below the sector average56.25% below the sector average
Operating Profit Loss
85.22% below the market average85.22% below the market average85.22% below the market average85.22% below the market average85.22% below the market average
52.17% below the sector average52.17% below the sector average52.17% below the sector average52.17% below the sector average52.17% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
8.24% above the market average8.24% above the market average8.24% above the market average8.24% above the market average8.24% above the market average
31.82% above the sector average31.82% above the sector average31.82% above the sector average31.82% above the sector average31.82% above the sector average
Cash
45.56% above the market average45.56% above the market average45.56% above the market average45.56% above the market average45.56% above the market average
55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y
15.94% above the market average15.94% above the market average15.94% above the market average15.94% above the market average15.94% above the market average
16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average
Buys 1y
70.57% above the market average70.57% above the market average70.57% above the market average70.57% above the market average70.57% above the market average
53.33% above the sector average53.33% above the sector average53.33% above the sector average53.33% above the sector average53.33% above the sector average

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 974.29p
Change Today -10.71p
% Change -1.09 %
52 Week High 1,600.00p
52 Week Low 974.29p
Volume 0
Shares Issued 15.50m
Market Cap £150.98m

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.48% below the market average65.48% below the market average65.48% below the market average65.48% below the market average65.48% below the market average
13.04% below the sector average13.04% below the sector average13.04% below the sector average13.04% below the sector average13.04% below the sector average
Price Trend
25.98% below the market average25.98% below the market average25.98% below the market average25.98% below the market average25.98% below the market average
13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average
Income Not Available
Growth
57.95% above the market average57.95% above the market average57.95% above the market average57.95% above the market average57.95% above the market average
67.74% above the sector average67.74% above the sector average67.74% above the sector average67.74% above the sector average67.74% above the sector average

4basebio Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page